Blue Trust Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 39.8% during the 4th quarter, Holdings Channel reports. The firm owned 724 shares of the biopharmaceutical company’s stock after purchasing an additional 206 shares during the quarter. Blue Trust Inc.’s holdings in Regeneron Pharmaceuticals were worth $516,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in REGN. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $37,000. Truvestments Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $49,000. Institutional investors own 83.31% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on REGN shares. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Finally, Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,004.57.
Regeneron Pharmaceuticals Stock Down 0.6 %
NASDAQ:REGN opened at $683.08 on Friday. The company has a market cap of $75.06 billion, a PE ratio of 16.90, a PEG ratio of 1.59 and a beta of 0.10. The stock has a 50-day simple moving average of $723.36 and a 200 day simple moving average of $928.61. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
See Also
- Five stocks we like better than Regeneron Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- What Makes a Stock a Good Dividend Stock?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Best Aerospace Stocks Investing
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.